Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.59
+0.47 (+0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
55
56
Next >
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
September 02, 2022
Via
Benzinga
Here's How Much $1000 Invested In AstraZeneca 5 Years Ago Would Be Worth Today
September 01, 2022
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 5.5% on an annualized basis producing an average annual return of 15.24%. Currently, AstraZeneca has a market...
Via
Benzinga
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
August 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
August 29, 2022
Upgrades
Via
Benzinga
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
August 29, 2022
Via
Benzinga
AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure
August 29, 2022
AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress.
Via
Benzinga
Week In Review: China And The US May Settle De-Listing/Accounting Impasse
August 27, 2022
China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. The list of affected biopharma companies includes BeiGene, Legend Bio,...
Via
Talk Markets
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
August 27, 2022
From
AstraZeneca
Via
Business Wire
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
August 27, 2022
From
AstraZeneca
Via
Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 25, 2022
Via
Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
August 25, 2022
Via
Benzinga
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
August 24, 2022
In a Reuters report, AstraZeneca Plc's (NASDAQ:
Via
Benzinga
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
August 24, 2022
From
AstraZeneca
Via
Business Wire
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
August 23, 2022
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured...
Via
Benzinga
Amgen Touts Positive Data From Soliris-Based Biosimilar For Rare Blood Disorder
August 23, 2022
Via
Benzinga
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
August 22, 2022
Via
Benzinga
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
August 17, 2022
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 16, 2022
Via
Benzinga
3 Top Stocks to Invest In Right Now
August 16, 2022
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense.
Via
InvestorPlace
Benzinga Before The Bell: Elon Musk May Get Info It Wants From Twitter, Apple To Lay Off 100 Recruiter Contractors, Saudi's Investment Fund Picks Stocks Of US Big Tech And Other Top Financial Stories Tuesday, August 16
August 16, 2022
Reuters
Via
Benzinga
UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment
August 16, 2022
Via
Benzinga
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
August 16, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use
August 16, 2022
Via
Benzinga
Benzinga Before The Bell: YouTube Plans Streaming Marketplace, Drug Pricing Bill Passes Congress, Bitcoin Could Surge To All-Time High Soon And Other Top Financial Stories Monday, August 15
August 15, 2022
Reuters PlayAGS Shares Pop Premarket On Takeover Offer At 33% Premium
Via
Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
August 15, 2022
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year...
Via
Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
August 15, 2022
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 12, 2022
Via
Benzinga
Blue Water Vaccines: Early Stage Developer Of Infectious Disease Vaccines
August 12, 2022
Is BWV a buy? We sat down with Blue Water Vaccines management to find out what the company has been up to and what have in store for the future.
Via
Talk Markets
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
August 12, 2022
Via
Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
August 12, 2022
From
AstraZeneca
Via
Business Wire
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.